Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » Compliance Mentor » FCA Claim Brought Against McKesson for Overfill Repackaging

    Compliance Mentor
    Compliance Mentor RSS FeedRSS

    compliance-mentor-static-reliasmedia

    Free Monthly News from the Award Winning Publisher of:

    • Hospital Access Management
    • Hospital Case Management
    • Hospital Employee Health
    • Hospital Infection Control
    • Hospital Peer Review
    • Healthcare Risk Management
    • Case Management Advisor
    • IRB Advisor
    • Medical Ethics Advisor
    • Same-Day Surgery

     

    FCA Claim Brought Against McKesson for Overfill Repackaging

    April 26, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Robert B. Vogel, MD, JD

    Robert B. Vogel, MD, JD
    Retinal Ophthalmologist at Piedmont Eye Center, Lynchburg VA;
    Attorney, Overbey Hawkins & Wright, PLLS, Lynchburg, VA;
    Adjunct Professor, Humanities and Bioethics, Liberty University School of Medicine, Lynchburg, VA.

    McKesson Corp., one of the nation’s largest pharmaceutical companies, and two of its subsidiaries have had federal and state False Claims Act allegations filed against them on behalf of the federal government, 30 state governments, and the city governments of Chicago, New York City, and the District of Columbia. The complaint alleges that McKesson overfilled bottles of single-use oncology and blood cell medications and skimmed the excess for repackaging.

    The filing alleges that from 2001 to 2010 McKesson took the overfill from its drug bottles, repackaged the drugs, and then distributed them to medical providers who sought government reimbursement for the drugs. The United States Pharmacopeial Convention permits the single-use vials of these medications to be slightly overfilled to allow for proper dosing. Federal Drug Administration guidelines, however, do not allow improper overfill, do not allow the overfill to be billed, and do not allow adulterated medications that are repackaged in unapproved facilities to be billed.   

    The complaint alleges that McKesson knowingly harvested overfill and then pooled the oncology drugs in plastic prefilled syringes and resold the syringes to medical practices who used them for chemotherapy and other treatments for oncology patients. The filing also asserts that prefilled syringes were filled in unsterile environments. The bottles from which the overfill was harvested were marked for single use. Because the price of the prefilled syringes was lower than the single-use vials, the government claims that it overpaid for these medications.

    Under the FCA, the defendants would be liable for knowingly submitting false claims to the government healthcare programs by causing a medical professional to use the adulterated product and then submit a claim for reimbursement. The complaint also alleges that by inducing medical professionals to use this product, McKesson violated the Anti-Kickback Statute (AKS). Violations of the AKS can be filed as FCA violations.

     


    Robert B. Vogel, MD, JD
    Retinal Ophthalmologist at Piedmont Eye Center, Lynchburg VA;
    Attorney, Overbey Hawkins & Wright, PLLS, Lynchburg, VA;
    Adjunct Professor, Humanities and Bioethics, Liberty University School of Medicine, Lynchburg, VA.



    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Compliance Mentor

    View PDF
    Compliance Mentor - April 2018
    April 1, 2018

    Table Of Contents

    Medical Device Company Alere to Pay $33.2 Million to Settle FCA Allegations

    CMS Issues Final Rule to Increase Health Insurance Affordability

    CMS Announces 2019 Medicare Advantage and Part D Rates and Other Changes

    FCA Claim Brought Against McKesson for Overfill Repackaging

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing